MYC and hepatocellular carcinoma: Currently undergoing evaluation in a Phase I/II trial, OTX-2002 is being investigated as a monotherapy and in combination with standard treatments in patients with HCC and other solid tumor types linked to the MYC oncogene (NCT05497453).